Duke University

The Brigham and Women's Hospital, Inc.

Case Western Reserve University

Other

University Hospitals Cleveland Medical Center

Nitromed, Inc.

Johns Hopkins University

Harvard College

The University of Texas System

Children's Medical Center Corporation

Boston University

The Medical College of Wisconsin, Inc.

Cornell Research Foundation Inc.

University of Virginia Patent Foundation

Research Development Foundation

Jonathan S Stamler

Eric John Toone

Joseph Loscalzo

Timothy J McMahon

Richard S Stack

Owen W Griffith

Mark W Dewhirst

Daniel Simon

Andrew J Gow

Pierre D Sonveaux

David J Singel

John D Folts

Joseph Bonaventura

Alfred Hausladen

Joshua Hare

Claude A Piantadosi

Jeffrey M Drazen

William Greenlee

Limin Liu

Focco Van Den Akker

Raphael Nudelman

Robert Brown

Adam Slivka

Stuart Arthur Lipton

Robert J Lefkowitz

R Michael Angelo

Benjamin M Gaston

Walter J Koch

Erin J Whalen

John R Pawloski

Lester Kobzik

Zhiqiang Chen

Gregory T Went

Inigo Saenz De Tejada

Brian J Day

Steven S Gross

Jordan U Gutterman

Scott Everett Blomberg

Tor Savidge

Mark Peterson

Jim A Berilla

Amanda Marie Franey

Goran Hedenstierna

John Baillie

Yehia Daaka

Liang Xie

Akio Matsumoto

Dean Le

Marcus Kaul

Kevin P Hurley

Marieann E Hogman

Claes G Frostell

James D Reynolds

Stephen O Vaughan

Joeseph Loscalzo

Harihara Baskaran

Michael Forrester

Thomas Munzel

Matthew Foster

Jordan Gutterman

Michael Angelo

Benjamin Gaston

Devices and methods are provided herein for exchange between a first agent and a second agent. The device includes a first chamber having a first inlet and a first outlet with a first flow passageway extending between the first inlet and the first outlet for flowing a first agent through the first chamber. The device also includes a second chamber having a second inlet and a second outlet with a second flow passageway extending between the second inlet and the second outlet for flowing a second agent through the second chamber and a membrane positioned between the first flow passageway and the second flow passageway to allow exchange through the membrane of the first agent with the second agent. Methods of nitrosylating blood and methods of manufacturing the device are also provided.

Devices and methods for nitrosylation of blood

An aldoketo reductase inhibitor includes a xanthene analogue.

Aldoketo reductase inhibitors and uses thereof

Devices for delivering a controlled concentration of an agent are provided. The device includes a reservoir for the agent and a flow control portion operably connected to the reservoir. The device also includes a valve for releasing the agent from the flow control portion and a pump for flowing air to mix with the agent released by the valve and for flowing the agent and air mixture out of the device. Methods of delivering a vaporized agent to a subject are also provided. The methods include storing a liquid agent in a reservoir of a device and flowing the agent into a flow control chamber to change the agent to a gas. The methods also include mixing the agent in gas form with air and flowing the agent and air mixture out of the device to be delivered to a subject.

Vaporization system for delivery in a controlled concentration

Aldoketo reductase (AKR) inhibitors having formulas I-III are used to treat disorders associated with NO/SNO deficiency.

A method for preventing or treating a tissue injury and/or promoting tissue repair in a subject in need thereof, includes administering to the subject a therapeutically effective amount of an ADH inhibitor, AKR inhibitor, SCoR inhibitor, and/or PKM2 inhibitor.

Compositions and methods for treating tissue injury

A method of lowering cholesterol and/or PCSK9 levels in a subject in need thereof includes administering to the subject an ADH inhibitor, AKR inhibitor, and/or SNO-CoAR inhibitor at an amount(s) effective to reduce serum cholesterol and/or PCSK9 levels.

Compositions and methods of reducing serum cholesterol and PCSK9

A method of treating coronavirus infection, post-acute sequelae of coronavirus infection, and viral mediated respiratory distress in a subject in need thereof includes administering to the subject a therapeutically effective amount of agent that promotes, increases, and/or induces hemoglobin nitrosylation within red blood cells (RBCs) and GSNO levels in the lung or airways of the subject.

Compositions and methods for in vivo lung and blood SNO repletion

A method of treating cardiovascular disorders and diseases in a subject in need thereof includes administering to the subject an ADH inhibitor, AKR inhibitor, and/or SNO-CoAR inhibitor at an amount(s) effective to promote S-nitrosylation of proteins in the subject, wherein the ADH inhibitor and/or SNO-CoAR inhibitor is not an ADH3 inhibitor.

Compositions and methods of modulating S-nitrosylation

A method of treating disorders associated with NO/SNO deficiency or benefiting from increased SNO in a subject in need thereof includes administering to the subject an ADH inhibitor, AKR inhibitor, SNO-CoAR inhibitor, and/or SNO-CoA at an amount(s) effective to promote S-nitrosylation of proteins in the subject.

Compositions and methods of modulating s-nitrosylation

Provided herein are methods for ameliorating the pathophysiology cysteine protease exotoxin comprising the step of administering to said individual an effective dose of an S-nitrosylating agent and an inositol phosphate or analog thereof.

S-nitrosylation of glucosylating toxins and uses therefor

An exemplary apparatus for measuring nitric oxide in a fluid includes a sample injection port; a pump and reservoir; a valve; a measurement chamber; an electromagnetic radiation source; controls and user interface; and a cartridge. The cartridge includes a sample chamber a mix chamber; a sample degassing chamber; and a planar reaction chamber. The cartridge preferably is single-use and disposable. Furthermore, additional inventive aspects and features are disclosed related to measuring nitric oxide in a fluid.

Methods and apparatus for measuring nitric oxide in fluid

Amount of combined nitric oxide or nitric oxide presented as iron nitrosyls in a blood sample is determined by directing a low power electromagnetic radiation beam at a blood sample to liberate nitric oxide gas, dissolving the liberated nitric oxide gas and electrochemically detecting amount of dissolved nitric oxide gas.

Method for liberating and detecting nitric oxide from nitrosothiols and iron nitrosyls in blood

A resin connected by amide bond to pyridyl sulfide or methylthiosulfonate can be conjugated to a post traditionally modified protein/peptide to allow determination of presence and kind and optionally location of cysteine modification(s).

Resin assisted capture of cysteine-modified proteins/peptides and determination of presence and location of modification

Growing community of inventors

Chapel Hill, NC, United States of America

Jonathan S Stamler